Company

Atley Solutions was founded on decades of pioneering research in targeted alpha therapy conducted by the renowned Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg, Sweden. Our roots lie in the early development of automatic astatine-211 (At-211) radiopharmaceuticals production, led by scientific co-founders Dr. Emma Aneheim and Dr. Sture Lindegren.

Today, Atley Solutions is a team of life science entrepreneurs, radiochemists, engineers, and business leaders united by a shared mission: to unlock the full potential of At-211. Combining deep scientific expertise with operational excellence, we are solving the challenges of scalable, GMP-compliant manufacturing and supply chain integration—enabling the commercialization of next-generation cancer therapies based on At-211.